The Future of Immuno-oncology in Advanced Lung Cancer

The Future of Immuno-oncology in Advanced Lung Cancer

ASCO 2016 – Lung Cancer

Benjamin P. Levy, MD, discusses the value in leveraging clinical trials to determine the potential of utilizing checkpoint inhibitors as single agent first line therapies and in combination with chemotherapy as a second line strategy.

Related Items

IFCT-1001 CHIVA trial: A phase II study of carboplatin (Ca) plus pemetrexed (P) followed by P maintenance, as first-line therapy for human immunodeficiency virus (HIV)-associated advanced non-squamous non-small-cell lung cancer (NS-NSCLC)

American Society of Clinical Oncology (ASCO)

ASCO 2016 – Lung Cancer

A phase II open-label single-arm study of vandetanib in patients with advanced RET-rearranged non-small cell lung cancer (NSCLC): Luret study

American Society of Clinical Oncology (ASCO)

ASCO 2016 – Lung Cancer

A randomized, open label, phase II study comparing pemetrexed plus cisplatin followed by pemetrexed versus pemetrexed alone in EGFR mutant NSCLC patients who have failed first-line EGFR TKI: KCSG-LU12-13

American Society of Clinical Oncology (ASCO)

ASCO 2016 – Lung Cancer

Alectinib (ALC) versus crizotinib (CRZ) in ALK-inhibitor naive ALK-positive non-small cell lung cancer (ALK+ NSCLC): Primary results from the J-ALEX study

American Society of Clinical Oncology (ASCO)

ASCO 2016 – Lung Cancer

An open-label phase 2 trial of dabrafenib (D) in combination with trametinib (T) in patients (pts) with previously treated BRAF V600E–mutant advanced non-small cell lung cancer (NSCLC; BRF113928)

American Society of Clinical Oncology (ASCO)

ASCO 2016 – Lung Cancer

Avelumab (MSB0010718C; anti-PD-L1) as a first-line treatment for patients with advanced NSCLC from the JAVELIN solid tumor phase 1b trial: Safety, clinical activity, and PD-L1 expression

American Society of Clinical Oncology (ASCO)

ASCO 2016 – Lung Cancer

Bayesian randomized trial comparing intensity-modulated radiation therapy versus passively scattered proton therapy for locally advanced non–small-cell lung cancer

American Society of Clinical Oncology (ASCO)

ASCO 2016 – Lung Cancer

Cost effectiveness of immune checkpoint inhibitors in NSCLC according to PD-L1 expression

American Society of Clinical Oncology (ASCO)

ASCO 2016 – Lung Cancer

E1505: Adjuvant chemotherapy ± bevacizumab for early stage NSCLC—outcomes based on chemotherapy subsets

American Society of Clinical Oncology (ASCO)

ASCO 2016 – Lung Cancer

Efficacy and safety of crizotinib in patients (pts) with advanced MET exon 14-altered non-small cell lung cancer (NSCLC)

American Society of Clinical Oncology (ASCO)

ASCO 2016 – Lung Cancer